Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

多发性骨髓瘤 医学 来那度胺 耐火材料(行星科学) 癌症研究 泊马度胺 肿瘤科 内科学 生物 天体生物学
作者
Wen-Ming Chen,Chengcheng Fu,Baijun Fang,Aibin Liang,Zhongjun Xia,Yanjuan He,Jin Lü,Hui Liu,Ming Hou,Zhen Cai,Wei Yang,Siguo Hao,Songfu Jiang,Hongmei Jing,Jing Liu,Xin Du,Rong Fu,Heng Mei,Zunmin Zhu,Yanli Yang
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 4564-4565 被引量:16
标识
DOI:10.1182/blood-2022-168610
摘要

Background: Zevorcabtagene autoleucel (Zevor-cel, CT053), a fully human autologous anti- B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell, is under investigation in patients (pts) with relapsed/refractory multiple myeloma (RRMM) of an ongoing phase 1/2 study, LUMMICAR STUDY1 (NCT03975907) in China. Results from the phase 1 LUMMICAR STUDY1 indicated that Zevor-cel is well tolerated with encouraging efficacy of an overall response rate (ORR) of 100% and very good partial response or better (≥VGPR) rate of 92.9% in 14 pts evaluated by investigators. Here we report for the first time the safety and efficacy data from the phase 2 pivotal study of LUMMICAR STUDY1. Methods: All patients had received ≥3 prior lines of therapies, including at least an immunomodulatory drug and a proteasome inhibitor regardless exposure to an anti-CD38 antibody. All subjects were relapse or refractory to the last line of therapy. After lymphodepletion (fludarabine at 25mg/m2 and cyclophosphamide at 300 mg/ m2 daily for 3 consecutive days), patients received a recommended phase 2 dose (RP2D) of 1.5 ×108 Zevor-cel (permit 1.8×108 Zevor-cel when body weight over 80 kilogram). Disease response was evaluated by independent review committee (IRC) per the IMWG 2016 criteria. Cytokine release syndrome (CRS) and Immune effector cell-associated neurotoxicity syndrome (ICANS) were graded according to ASTCT CRS consensus grading system (Lee DW et al, 2019). Minimal residual disease (MRD) was tested by next-generation flow cytometry on bone marrow aspirates by the EuroFlow assay at a minimum sensitivity of 10-5. CAR copies in the patient peripheral blood were monitored by quantitative real-time polymerase chain reaction (qPCR). Results: Between December 1st, 2020, and March 2nd, 2022, 102 eligible patients received Zevor-cel . Among them, the median age was 59.5 years (38 to 75) and the median prior lines of therapy were 4 (3 to 15). 24 (23.5%) patients ever received auto-ASCT, 91 (89.2%) patients were double refractory, and 23 (22.5%) patients were triple refractory. 39 (38.2%) patients had stage III disease at screening according to International Staging System, 7 (6.9%) patients had extramedullary disease (EMD), and 46 (45.1%) patients had high-risk cytogenetic abnormality, defined as del(17p), t(4;14), t(14;16), or t(14;20). At the time of data cutoff (March 30, 2022), 102 patients had at least 1 month safety data and 83 patients had at least 3 months efficacy follow-up. Of the 83 patients, with a median follow-up of 227 (11,437) days, the overall response (partial response [PR] or better) rate per IRC was 92.8% (95%CI, 84.9-97.3), complete response/ stringent complete response (CR/sCR) rate was 42.2% (95%CI, 31.4-53.5), and the rate of very good partial response (VGPR) and above was 81.9% (95%CI, 72.0-89.5). The median progression-free survival (PFS) was not reached, and the 6-month PFS rate was 90.2% (95%CI, 80.4-95.2). The median duration of objective response (DoR) was not reached, and the probabilities of the responders remaining in response at 6 months were 92.2% (95% CI,80.1-97.1). MRD status was assessed in patients achieving VGPR and better. MRD negative (<10−5 nucleated cells) was confirmed in 95.2% CR/sCR patients and in 88.3% VGPR and better patients respectively. CRS was reported in 92 patients (90.2%), including 7 (6.9%) who had events of grade 3/4, and all grade 3 or 4 CRS were fully recovered. ICANS developed in 2 (2%) patients and both were of grade 1, no neurotoxic effects of grade 3 or higher occurred. Frequently reported treatment related adverse events including hypogammaglobulinemia (23.5%) and pneumonia (24.5%) were manageable and reversible. Four deaths occurred in the study and none due to treatment related adverse events. The CAR copies were detected at serial points after infusion. The median time of Zevor-cel CAR copies reaching peak was 14 days (3-22 days) and the median time of persistence was 77 days (3-283 days), with detectable CAR copies in 44% (20/45) patients at 6 months after infusion. Conclusions: These preliminary data demonstrate that targeting BCMA with Zevor-cel results in deep and durable responses in patients with r/r MM. A well-tolerated safety profile similar to other BCMA targeting cell therapy was established.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
4秒前
qiancib202完成签到,获得积分0
4秒前
4秒前
ice发布了新的文献求助10
7秒前
迅速的念芹完成签到 ,获得积分10
8秒前
10秒前
Dogged完成签到 ,获得积分10
12秒前
cfw完成签到,获得积分10
12秒前
大意的火龙果完成签到 ,获得积分10
12秒前
Harold完成签到,获得积分10
16秒前
cfw发布了新的文献求助10
16秒前
幸运小张完成签到,获得积分0
17秒前
乐观寻芹完成签到,获得积分10
21秒前
从容的水壶完成签到 ,获得积分10
22秒前
彩色人生完成签到 ,获得积分10
24秒前
25秒前
daikai完成签到 ,获得积分10
25秒前
宗剑完成签到,获得积分10
28秒前
心无杂念完成签到 ,获得积分10
29秒前
LJ_2完成签到 ,获得积分0
36秒前
高贵觅山完成签到,获得积分10
36秒前
keyan完成签到,获得积分10
38秒前
Shulug完成签到 ,获得积分10
38秒前
李可以完成签到 ,获得积分10
40秒前
weven完成签到 ,获得积分10
44秒前
foyefeng完成签到,获得积分10
46秒前
lllll完成签到 ,获得积分10
1分钟前
lzr完成签到 ,获得积分10
1分钟前
友好的晓曼完成签到,获得积分10
1分钟前
白鱼neko完成签到 ,获得积分10
1分钟前
木卫二完成签到 ,获得积分10
1分钟前
xiaoxiao完成签到 ,获得积分10
1分钟前
momo完成签到 ,获得积分10
1分钟前
风格完成签到,获得积分10
1分钟前
1分钟前
水煮电吹风的应助被雪山飞龙采纳,获得10
1分钟前
醉酒当歌完成签到 ,获得积分10
1分钟前
侯子完成签到 ,获得积分10
1分钟前
追寻微笑完成签到 ,获得积分10
1分钟前
勤劳的唇膏完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180053
求助须知:如何正确求助?哪些是违规求助? 9570224
关于积分的说明 21808682
捐赠科研通 7776054
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557425
邀请新用户注册赠送积分活动 2479012